Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H25N3O7S |
Molecular Weight | 475.515 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC4=CC=CC(=C4)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
InChI
InChIKey=JUZNIMUFDBIJCM-ANEDZVCMSA-N
InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1
Molecular Formula | C22H25N3O7S |
Molecular Weight | 475.515 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/ppa/ertapenem.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22 | http://www.rxlist.com/invanz-drug.htm
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/ppa/ertapenem.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22 | http://www.rxlist.com/invanz-drug.htm
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%), and vomiting (1.1%). The coadministration with probenecid to extend the half-life of ertapenem is not recommended.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
|||
Target ID: P0AD65 Gene ID: 945240.0 Gene Symbol: mrdA Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10223931 |
|||
Target ID: P0AD68 Gene ID: 944799.0 Gene Symbol: ftsI Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10223931 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | INVANZ Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2) Launch Date2001 |
|||
Curative | INVANZ Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2) Launch Date2001 |
|||
Curative | INVANZ Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2) Launch Date2001 |
|||
Curative | INVANZ Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2) Launch Date2001 |
|||
Curative | INVANZ Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2) Launch Date2001 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12709348 |
1 g 1 times / day multiple, intramuscular dose: 1 g route of administration: Intramuscular experiment type: MULTIPLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
70.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12709348 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
155 μg/mL |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
663.1 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02159859 |
1 g 3 times / week multiple, intravenous dose: 1 g route of administration: intravenous experiment type: multiple co-administered: |
ERTAPENEM plasma | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
506.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12709348 |
1 g 1 times / day multiple, intramuscular dose: 1 g route of administration: Intramuscular experiment type: MULTIPLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
541.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12709348 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6225 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02159859 |
1 g 3 times / week multiple, intravenous dose: 1 g route of administration: intravenous experiment type: multiple co-administered: |
ERTAPENEM plasma | Homo sapiens population: unhealthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12709348 |
1 g 1 times / day multiple, intramuscular dose: 1 g route of administration: Intramuscular experiment type: MULTIPLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12709348 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4 h |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
19.3 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02159859 |
1 g 3 times / week multiple, intravenous dose: 1 g route of administration: intravenous experiment type: multiple co-administered: |
ERTAPENEM plasma | Homo sapiens population: unhealthy age: sex: food status: |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ERTAPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 g 1 times / day steady, intravenous Highest studied dose Dose: 3 g, 1 times / day Route: intravenous Route: steady Dose: 3 g, 1 times / day Sources: |
healthy, 18-49 years Health Status: healthy Age Group: 18-49 years Sex: M+F Sources: |
|
500 mg 1 times / day steady, intravenous (starting) Dose: 500 mg, 1 times / day Route: intravenous Route: steady Dose: 500 mg, 1 times / day Co-administed with:: vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day) Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: M Population Size: 1 Sources: |
Disc. AE: Encephalopathy... AEs leading to discontinuation/dose reduction: Encephalopathy (1 patient) Sources: |
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Co-administed with:: daptomycin(1 g daily) Sources: |
unhealthy, 71 years n = 1 Health Status: unhealthy Condition: osteomyelitis Age Group: 71 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hallucinations, Delirium... AEs leading to discontinuation/dose reduction: Hallucinations (1 patient) Sources: Delirium (1 patient) |
1 g 1 times / day steady, intravenous|intramuscular Recommended Dose: 1 g, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 1 g, 1 times / day Sources: Page: p. 184 |
unhealthy, adult n = 319 Health Status: unhealthy Age Group: adult Population Size: 319 Sources: Page: p. 184 |
Disc. AE: Rash, Confusion... AEs leading to discontinuation/dose reduction: Rash (1 patient) Sources: Page: p. 184Confusion (1 patient) Seizure (1 patient) Thrombocytopenia (1 patient) |
1 g 3 times / day single, intravenous Overdose Dose: 1 g, 3 times / day Route: intravenous Route: single Dose: 1 g, 3 times / day Sources: |
healthy n = 1 Health Status: healthy Population Size: 1 Sources: |
Other AEs: Diarrhea, Dizziness... Other AEs: Diarrhea (1 patient) Sources: Dizziness (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Encephalopathy | 1 patient Disc. AE |
500 mg 1 times / day steady, intravenous (starting) Dose: 500 mg, 1 times / day Route: intravenous Route: steady Dose: 500 mg, 1 times / day Co-administed with:: vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day) Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: M Population Size: 1 Sources: |
Delirium | 1 patient Disc. AE |
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Co-administed with:: daptomycin(1 g daily) Sources: |
unhealthy, 71 years n = 1 Health Status: unhealthy Condition: osteomyelitis Age Group: 71 years Sex: M Population Size: 1 Sources: |
Hallucinations | 1 patient Disc. AE |
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Co-administed with:: daptomycin(1 g daily) Sources: |
unhealthy, 71 years n = 1 Health Status: unhealthy Condition: osteomyelitis Age Group: 71 years Sex: M Population Size: 1 Sources: |
Confusion | 1 patient Disc. AE |
1 g 1 times / day steady, intravenous|intramuscular Recommended Dose: 1 g, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 1 g, 1 times / day Sources: Page: p. 184 |
unhealthy, adult n = 319 Health Status: unhealthy Age Group: adult Population Size: 319 Sources: Page: p. 184 |
Rash | 1 patient Disc. AE |
1 g 1 times / day steady, intravenous|intramuscular Recommended Dose: 1 g, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 1 g, 1 times / day Sources: Page: p. 184 |
unhealthy, adult n = 319 Health Status: unhealthy Age Group: adult Population Size: 319 Sources: Page: p. 184 |
Seizure | 1 patient Disc. AE |
1 g 1 times / day steady, intravenous|intramuscular Recommended Dose: 1 g, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 1 g, 1 times / day Sources: Page: p. 184 |
unhealthy, adult n = 319 Health Status: unhealthy Age Group: adult Population Size: 319 Sources: Page: p. 184 |
Thrombocytopenia | 1 patient Disc. AE |
1 g 1 times / day steady, intravenous|intramuscular Recommended Dose: 1 g, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 1 g, 1 times / day Sources: Page: p. 184 |
unhealthy, adult n = 319 Health Status: unhealthy Age Group: adult Population Size: 319 Sources: Page: p. 184 |
Diarrhea | 1 patient | 1 g 3 times / day single, intravenous Overdose Dose: 1 g, 3 times / day Route: intravenous Route: single Dose: 1 g, 3 times / day Sources: |
healthy n = 1 Health Status: healthy Population Size: 1 Sources: |
Dizziness | 1 patient | 1 g 3 times / day single, intravenous Overdose Dose: 1 g, 3 times / day Route: intravenous Route: single Dose: 1 g, 3 times / day Sources: |
healthy n = 1 Health Status: healthy Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
Page: (Pharm) 9, (ClinP) 3, 23 |
no [IC50 >500 uM] | |||
Page: (Pharm) 9, (ClinP) 3, 23 |
no [IC50 >500 uM] | |||
Page: (Pharm) 9, (ClinP) 3, 23 |
no [IC50 >500 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
no | ||||
yes [IC50 56.2 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_biopharmr.pdf#PAGE=3 Page: (ClinP) 3 |
no | |||
no |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. | 2001 Aug |
|
Gateways to Clinical Trials. | 2002 Apr |
|
In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. | 2002 Aug |
|
Gateways to clinical trials. | 2002 Jan-Feb |
|
In vitro activity of ertapenem against bacterial isolates from cancer patients. | 2002 Jul |
|
Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli. | 2002 Jul 15 |
|
Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. | 2002 Jun |
|
Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections. | 2002 Jun |
|
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. | 2002 Jun 1 |
|
Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. | 2002 Mar |
|
Ertapenem (Invanz)--a new parenteral carbapenem. | 2002 Mar 18 |
|
Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. | 2002 May |
|
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. | 2002 Nov |
|
Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. | 2002 Nov |
|
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. | 2002 Nov |
|
Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation. | 2002 Nov 5 |
|
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. | 2002 Sep |
|
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. | 2002 Sep 1 |
|
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. | 2002 Sep 1 |
|
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. | 2002 Winter |
|
Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. | 2003 Aug |
|
New drugs 2003, part I. | 2003 Feb |
|
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. | 2003 Feb |
|
Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma. | 2003 Jan 5 |
|
[New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam]. | 2003 Jul-Sep |
|
[Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria]. | 2003 Jun |
|
Ertapenem therapy for community-acquired pneumonia in the elderly. | 2003 Nov |
|
New therapies for pneumococcal meningitis. | 2004 Apr |
|
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam. | 2004 Feb |
|
Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions. | 2004 Jan 1 |
|
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. | 2004 Jun |
|
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. | 2004 Jun |
|
Gateways to clinical trials. | 2004 Mar |
|
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition. | 2004 May 1 |
|
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. | 2005 Mar |
|
In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains. | 2005 Mar |
Sample Use Guides
1 g given once a day. Intravenous infusion for up to 14 days or intramuscular injection for up to 7 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22547617
The MICs of ertapenem are MIC(50) = 0.032 μg/ml; MIC(90) = 0.064 μg/ml in vitro activity of ertapenem against N.gonorrhoeae isolates.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:59:28 GMT 2023
by
admin
on
Fri Dec 15 15:59:28 GMT 2023
|
Record UNII |
G32F6EID2H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000175496
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
WHO-ATC |
J01DH03
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NCI_THESAURUS |
C260
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
WHO-VATC |
QJ01DH03
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
NDF-RT |
N0000011294
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
||
|
LIVERTOX |
NBK548006
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
G32F6EID2H
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
Ertapenem
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
G32F6EID2H
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
C446479
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
325642
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB25388
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
1046
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
m5001
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00303
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
8020
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
153832-46-3
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
150610
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
404903
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
C61752
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
100000089365
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
8049
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
DTXSID50165456
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1359
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY | |||
|
ERTAPENEM
Created by
admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
ENZYME->SUBSTRATE |
Low level activity could still lead to resistance to the antibiotic.
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||